ARTICLE | Clinical News
Vosaroxin regulatory update
May 7, 2012 7:00 AM UTC
The European Commission granted Orphan Drug designation for Sunesis' vosaroxin to treat acute myelogenous leukemia (AML). Vosaroxin is in the Phase III VALOR trial in patients with relapsed or refract...